GSK took center stage last month, forming standout partnerships and alliances across multiple therapeutic areas.

Explore how biotech breakthroughs in 2024 have changed lives, bringing real Christmas miracles to patients and offering hope ...

Bugworks, which is headquartered in the U.S. with subsidiaries in India and Australia, specializes in the development of antibiotics that could address the growing crisis of antimicrobial resistance.

Idiopathic pulmonary fibrosis (IPF) is a rare condition where the lungs become scarred, making it hard to breathe. The cause of the disease is unknown, which is why it is called ‘idiopathic.’ So far, ...

Asking whether China is the future of the biotech industry might seem counterintuitive, considering the current biotech geopolitical context. If you haven’t followed this series of events, a ...

As touched upon, a few decades ago, Japan was a global powerhouse when it came to biopharma innovation, as companies in the country invested heavily in research and development (R&D), aided at the ...

The biggest private biotech funding round of November 2024 went to Metsera, which raised $215 million in series B funding. The company is focused on advancing the next generation of therapies for ...

One of the biggest buyouts last month was Swiss pharma giant Roche’s $1.5 billion dollar acquisition of cell and gene therapy developer Poseida Therapeutics. This will see Roche nab the CAR-T ...

The integration of artificial intelligence (AI) in the biotech industry seems boundless. Its combination with CRISPR could be the one area where AI has the most potential. Nobel prize winner and ...

Progressing a drug through clinical trials relies on a robust evidence generation plan that includes a strong trial design, accurate patient recruitment and treatment effect assumptions, and ...